The global needle-free drug delivery devices market size to be valued at USD 16.26 billion by 2025 and is expected to grow at a compound annual growth rate (CAGR) of 10.5% during the forecast period. Widening base of diabetic patients and increasing ease in access to type1 diabetes are likely to stimulate the growth of the market during the forecast period. Conventionally, Type 1 diabetes patients requiring regular glucose monitoring use needles, which increases the risk of infection and pain among individuals. Needle-free devices provide pain less delivery and negate the risk of infection. As a result, the demand for these devices is expected to increase during the forecast period.
Furthermore, surging demand and technological advancements in the field of pain-free drug transportation and self-administration have been playing an instrumental role in driving the market. For instance, Zogenix had introduced DosePro, a needle-free medication transportation technology in 2015, which is a prefilled, single-use. and disposable subcutaneous medicine transportation system for self-administration of liquid medicine formulations.
Rising pressure to curb the incidence rate of infectious diseases such as hepatitis, dengue fever, neurological disorders, and AIDS caused by West Nile virus during transmission is estimated to bode well for the growth of the market during the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2015, about 47,352 individuals were diagnosed with HIV infection, of which 3,096 individuals were attributed to the injection drug use (IDU).
The primary driver for this market is the increasing incidence of chronic diseases such as HIV AIDS, dengue, and hepatitis. Needle-free devices reduce pain and decrease the risk of infection, making them preferable to standard procedures. Thus, the increasing availability of these devices and the presence of well-developed healthcare facilities in developed countries are expected to drive market growth. Furthermore, increasing initiatives by government organizations and pharmaceutical companies to sponsor extensive research and development costs for diabetes and chronic pain cases are also expected to have a positive impact on the market.
The high investment in the initial cost of needle-free drug delivery devices is likely to hamper the growth of the market. Several countries cannot afford needle-free drug delivery devices. Additionally, a lack of awareness among underdeveloped and developing countries is also restraining the market growth.
A significant opportunity for this market is technological advancements for pain-free drug transportation. The emergence of a self-administrative disposable subcutaneous medication transportation system is expected to increase the demand among patients during the forecast period.
The transdermal patch has gained popularity over the years owing to associated advantages such as maintaining constant drug levels, fewer side effects, and effective absorption of medications, which couldn’t be absorbed via GI tract. Additionally, as the substance is released evenly and directly into the bloodstream, less amount of medicine is required. Owing to the aforementioned factors, the segment is anticipated to register the highest growth during the forecast period are anticipated to boost the demand for transdermal patches in coming years.
In 2017, jet injectors accounted for the largest share in the market, due to benefits associated with them over other traditional drug transportation devices with needles. These benefits include faster drug delivery into bloodstream and insulin distribution over a larger area in lower layer of an individual's skin.
Jet injectors are utilized for a wide array of applications owing to their merits such as rapid administration, improved dosing accuracy, faster response rates, and better diffusion into tissues, reduced pain, reduced sharp waste, and easy portability. However, they can also be utilized for potential applications such as local anesthesia, intralesional corticosteroids, Direct palmar (BoNT-ONA, onabotulinum toxin A) BoNT-ONA, intralesional bleomycin, and Intralesional 5-ALA. These factors are projected to help the market remain dominant until 2025.
Insulin delivery was the most prominent application segment in the needle-free drug delivery device market in 2017. The growth of the segment can be to rising incidence of diabetes and increasing shift towards unhealthy lifestyle habits. For instance, according to the Centers for Disease Control and Prevention, about 30.3 million individuals were affected by diabetes globally in 2017, of which 9.4% were U.S. citizens. However, about 23.1 million people were diagnosed and 7.2 million remained undiagnosed.
Moreover, owing to introduction of technologically advanced products such as insulin micropump, insulin pen, insulin spray, inhalable insulin, and other novel jet injectors, the insulin delivery segment is poised to post a lucrative CAGR during the forecast period. For instance, by 2019, Novartis is expected to launch an EpiPen that will cost around $250.0 and is cheaper than other EpiPen products available in the market. Additionally, Zeneno by Crossject is likely to be launched in the coming years and is estimated to have a lower target price.
In addition, the pain management segment held a sizeable share in the market owing to mounting cases of medical conditions such as chronic pain, pain disorder, myofascial pain syndrome, arthritis, and migraines. For instance, according to the American Pain Foundation Chronic in 2017, pain affected about 40-50 million Americans per year.
North America accounted for approximately 44.0% of the overall revenue in 2017. High awareness regarding potential benefits of needle-free drug delivery devices has supported the dominance of the region in the global arena. Moreover, presence of well-developed healthcare facilities and extensive R&D expenditure by government organizations and pharmaceutical companies for diabetes and chronic pain management are also contributing to the growth of the market.
The Asia Pacific market is anticipated to witness lucrative growth over the forecast year owing to rising prevalence of diabetes in developing countries such as India and China. For instance, the International Diabetes Federation states that in 2017, India had about 7.2 billion individuals suffering from diabetes and China had about 11.4 billion individuals suffering from diabetes.
The needle-free drug delivery device market is marked by presence of various small and large companies. It is competitive in nature and dominated by key market players such as Antares Pharma, 3M, and Injex Pharma AG. Some other key players are Verdict Media Limited; Pharmajet; Zonenix; Inovio Pharmaceuticals, Inc.; Valeritas, Inc.; and Penjet.
Companies are adopting strategies such as new product launch, regional expansion, partnership, and distribution agreements to increase their market penetration. For instance, in October 2017, Antares Pharma and Ferring Pharmaceuticals entered into a definitive agreement. The latter received fixed assets from Antares and rights to sell ZOMAJET, needle-free auto-injector, worldwide. Additionally, in 2017, Takeda and Portal Instruments collaborated with each other to develop and commercialize Portal’s needle free drug delivery device, which is to be used with biologic medicines offered by Takeda Pharmaceuticals. Such initiatives are projected to propel the market during the forecast period.
In August 2021, PharmaJet and its partner Zydus Cadila announced the development of ZyCoV-D, the world's first Plasmid DNA Vaccine for COVID-19, after receiving an Emergency Use Authorization (EUA). The ZyCoV-D vaccination is delivered with the PharmaJet Tropis needle-free injector
In October 2020, the University of Cambridge's study of DIOSynVax's candidate was chosen to use PharmaJet's Needleless vaccine injector to inject one of the COVID-19 vaccines. The vaccine was aimed to be delivered via skin without the use of needles
Revenue forecast in 2025
USD 16.26 billion
CAGR of 10.5% from 2018 to 2025
Base year for estimation
2014 - 2016
2018 - 2025
Revenue in USD million/billion and CAGR from 2018 to 2025
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Technology, application, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; Japan; China; India; Brazil; Mexico; South Africa
Key companies profiled
Antares Pharma, 3M, and Injex Pharma AG. Some other key players are Verdict Media Limited; Pharmajet; Zonenix; Inovio Pharmaceuticals, Inc.; Valeritas, Inc.; Penjet.
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global needle-free drug delivery devices market report on the basis of technology, application, and region:
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Transdermal patch technology
Novel needle-free technologies
Application Outlook (Revenue, USD Million, 2014 - 2025)
Insulin delivery for diabetes
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."